Skip to main content
Erschienen in: best practice onkologie 6/2014

02.12.2014 | CME_Topic

Interdisziplinäre Therapie des Ösophaguskarzinoms

verfasst von: Prof. Dr. F. Lordick, I. Gockel, J. Mössner, T. Kuhnt, C. Wittekind

Erschienen in: best practice onkologie | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Behandlung lokalisierter Ösophaguskarzinome wurde über Jahrzehnte kontrovers diskutiert. Die chirurgische Resektion wurde als die einzige kurative Behandlungsmodalität angesehen. In den letzten Jahren erwies sich die endoskopische Resektion bei sehr frühen Karzinomen, die nicht die Submukosa infiltrieren, als eine wirksame und sichere kurative Behandlungsoption. Die neoadjuvante Platin/5-FU-basierte Chemotherapie (CTx) wurde mittlerweile für die Behandlung lokal fortgeschrittener Adenokarzinome des Ösophagus und des ösophagogastralen Übergangs als Standard etabliert. Die neoadjuvante Radiochemotherapie (RCTx) mit Platin plus 5-FU oder Paclitaxel ist der Behandlungsstandard für resektable Plattenepithelkarzinome des Ösophagus der Kategorien cT3 und cT4a und kann auch für Adenokarzinome eingesetzt werden. Patienten mit Plattenepithelkarzinom, die mit definitiver RCTx behandelt und nicht reseziert werden, erreichen eine in etwa vergleichbare Überlebensprognose wie nach Operation. Die therapieassoziierte Letalität ist nach Operation höher, die lokale Tumorkontrolle aber signifikant besser. Trotz aller Fortschritte erreicht man über alle lokalisierten Stadien hinweg bei 30–60 % der Patienten keine langfristige Tumorkontrolle. Wirksamere Behandlungsregime werden dringend benötigt. Um bessere Ergebnisse zu erreichen, soll die kurative Therapie des Ösophaguskarzinoms an Zentren mit guter interdisziplinärer Zusammenarbeit, Qualitätssicherung und hoher Erfahrung erfolgen.
Literatur
[1]
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C (2010) TNM-Klassifikation maligner Tumoen, 7. Aufl. Wiley-VCH, Weinheim Sobin LH, Gospodarowicz MK, Wittekind C (2010) TNM-Klassifikation maligner Tumoen, 7. Aufl. Wiley-VCH, Weinheim
[2]
Zurück zum Zitat Gockel I, Sgourakis G, Lyros O et al (2011) Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol 5:371–384PubMedCrossRef Gockel I, Sgourakis G, Lyros O et al (2011) Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol 5:371–384PubMedCrossRef
[3]
Zurück zum Zitat Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459PubMedCrossRef Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459PubMedCrossRef
[4]
Zurück zum Zitat Mariette C, Piessen G, Briez N et al (2011) Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol 12:296–305PubMedCrossRef Mariette C, Piessen G, Briez N et al (2011) Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol 12:296–305PubMedCrossRef
[5]
Zurück zum Zitat Pohl H, Sirovich B, Welch G (2010) Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 19:1468–1470PubMedCrossRef Pohl H, Sirovich B, Welch G (2010) Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 19:1468–1470PubMedCrossRef
[6]
Zurück zum Zitat Sgourakis G, Gockel I, Lyros O et al (2011) Detection of lymph node metastases in esophageal cancer. Expert Rev Anticancer Ther 11:601–612PubMedCrossRef Sgourakis G, Gockel I, Lyros O et al (2011) Detection of lymph node metastases in esophageal cancer. Expert Rev Anticancer Ther 11:601–612PubMedCrossRef
[7]
Zurück zum Zitat Steyerberg EW, Neville BA, Koppert LB et al (2006) Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 24:4277–4284PubMedCrossRef Steyerberg EW, Neville BA, Koppert LB et al (2006) Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 24:4277–4284PubMedCrossRef
[8]
Zurück zum Zitat Adrichem EJ van, Meulenbroek RL, Plukker JT et al (2014) Comparison of two preoperative inspiratory muscle training programs to prevent pulmonary complications in patients undergoing esophagectomy: a randomized controlled pilot study. Ann Surg Oncol 21:2353–2360PubMed Adrichem EJ van, Meulenbroek RL, Plukker JT et al (2014) Comparison of two preoperative inspiratory muscle training programs to prevent pulmonary complications in patients undergoing esophagectomy: a randomized controlled pilot study. Ann Surg Oncol 21:2353–2360PubMed
[9]
Zurück zum Zitat Pech O, May A, Manner H et al (2014) Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 146:652–660PubMedCrossRef Pech O, May A, Manner H et al (2014) Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 146:652–660PubMedCrossRef
[10]
Zurück zum Zitat Lewis I (1946) The surgical treatment of carcinoma of the esophagus with special reference to a new operation for growths of the middle third. Br J Surg 34:18–31PubMedCrossRef Lewis I (1946) The surgical treatment of carcinoma of the esophagus with special reference to a new operation for growths of the middle third. Br J Surg 34:18–31PubMedCrossRef
[11]
Zurück zum Zitat McKeown KC (1976) Total three-stage esophagectomy for cancer of the esophagus. Br J Surg 63:259–262PubMedCrossRef McKeown KC (1976) Total three-stage esophagectomy for cancer of the esophagus. Br J Surg 63:259–262PubMedCrossRef
[13]
Zurück zum Zitat Merendino KA, Dillard DH (1955) The concept of sphincter substitution by an interposed jejunal segment for anatomic and physiologic abnormalities at the esophagogastric junction with special reference to reflux esophagitis, cardiospasm and esophageal varices. Ann Surg 142:486–506PubMedCentralPubMedCrossRef Merendino KA, Dillard DH (1955) The concept of sphincter substitution by an interposed jejunal segment for anatomic and physiologic abnormalities at the esophagogastric junction with special reference to reflux esophagitis, cardiospasm and esophageal varices. Ann Surg 142:486–506PubMedCentralPubMedCrossRef
[14]
Zurück zum Zitat Luketich JD, Pennathur A, Awais O et al (2012) Outcomes after minimally invasive esophagectomy. Review of over 1000 patients. Ann Surg 256:95–103PubMedCentralPubMedCrossRef Luketich JD, Pennathur A, Awais O et al (2012) Outcomes after minimally invasive esophagectomy. Review of over 1000 patients. Ann Surg 256:95–103PubMedCentralPubMedCrossRef
[15]
Zurück zum Zitat Palanivelu C, Prakash A, Senthilkumar R et al (2006) Minimally invasive esophagectomy: thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position-experience of 130 patients. J Am Coll Surg 203:7–16PubMedCrossRef Palanivelu C, Prakash A, Senthilkumar R et al (2006) Minimally invasive esophagectomy: thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position-experience of 130 patients. J Am Coll Surg 203:7–16PubMedCrossRef
[16]
Zurück zum Zitat Biere SS, Berge Henegouwen MI van et al (2012) Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-labeled, randomised controlled trial. Lancet 379:1887–1892PubMedCrossRef Biere SS, Berge Henegouwen MI van et al (2012) Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-labeled, randomised controlled trial. Lancet 379:1887–1892PubMedCrossRef
[17]
Zurück zum Zitat Lordick F, Stein HJ, Peschel C, Siewert JR (2004) Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91:540–551PubMedCrossRef Lordick F, Stein HJ, Peschel C, Siewert JR (2004) Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91:540–551PubMedCrossRef
[18]
Zurück zum Zitat Kelsen DP, Ginsberg R, Pajak TF et al (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979–1984PubMedCrossRef Kelsen DP, Ginsberg R, Pajak TF et al (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979–1984PubMedCrossRef
[19]
Zurück zum Zitat Medical Research Council Oesophageal Cancer Working Party (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 359:1727–1733CrossRef Medical Research Council Oesophageal Cancer Working Party (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 359:1727–1733CrossRef
[20]
Zurück zum Zitat Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692PubMedCrossRef Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692PubMedCrossRef
[21]
Zurück zum Zitat Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F et al (2013) Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol 24:2068–2073PubMedCrossRef Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F et al (2013) Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol 24:2068–2073PubMedCrossRef
[22]
Zurück zum Zitat Lordick F (2011) Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol 7:187–199PubMedCrossRef Lordick F (2011) Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol 7:187–199PubMedCrossRef
[23]
Zurück zum Zitat Lordick F, Kang YK, Chung HC et al (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14:490–499PubMedCrossRef Lordick F, Kang YK, Chung HC et al (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14:490–499PubMedCrossRef
[24]
[25]
Zurück zum Zitat Hagen P van, Hulshof MC, Lanschot JJ van et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084PubMedCrossRef Hagen P van, Hulshof MC, Lanschot JJ van et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084PubMedCrossRef
[26]
Zurück zum Zitat Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851–856PubMedCrossRef Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851–856PubMedCrossRef
[27]
Zurück zum Zitat Mariette C, Dahan L, Mornex F et al (2014) Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 32:2416–2422PubMedCrossRef Mariette C, Dahan L, Mornex F et al (2014) Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 32:2416–2422PubMedCrossRef
[28]
[29]
Zurück zum Zitat Takizawa K, Matsuda T, Kozu T et al (2009) Lymph node staging in esophageal squamous cell carcinoma: a comparative study of endoscopic ultrasonography versus computed tomography. J Gastroenterol Hepatol 24:1687–1691PubMedCrossRef Takizawa K, Matsuda T, Kozu T et al (2009) Lymph node staging in esophageal squamous cell carcinoma: a comparative study of endoscopic ultrasonography versus computed tomography. J Gastroenterol Hepatol 24:1687–1691PubMedCrossRef
[30]
Zurück zum Zitat Shimizu S, Hosokawa M, Itoh K et al (2009) Can hybrid FDG-PET/CT detect subclinical lymph node metastasis of esophageal cancer appropriately and contribute to radiation treatment planning? A comparison of image-based and pathological findings. Int J Clin Oncol 14:421–425PubMedCrossRef Shimizu S, Hosokawa M, Itoh K et al (2009) Can hybrid FDG-PET/CT detect subclinical lymph node metastasis of esophageal cancer appropriately and contribute to radiation treatment planning? A comparison of image-based and pathological findings. Int J Clin Oncol 14:421–425PubMedCrossRef
[31]
Zurück zum Zitat Wang YC, Hsieh TC, Yu CY et al (2012) The clinical application of 4D 18F-FDG PET/CT on gross tumor volume delineation for radiotherapy planning in esophageal squamous cell cancer. J Radiat Res 53:594–600PubMedCentralPubMedCrossRef Wang YC, Hsieh TC, Yu CY et al (2012) The clinical application of 4D 18F-FDG PET/CT on gross tumor volume delineation for radiotherapy planning in esophageal squamous cell cancer. J Radiat Res 53:594–600PubMedCentralPubMedCrossRef
[32]
Zurück zum Zitat Kole TP, Aghayere O, Kwah J et al (2012) Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 83:1580–1586PubMedCrossRef Kole TP, Aghayere O, Kwah J et al (2012) Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 83:1580–1586PubMedCrossRef
[33]
Zurück zum Zitat Lin SH, Wang L, Myles B et al (2012) Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 84:1078–1085PubMedCentralPubMedCrossRef Lin SH, Wang L, Myles B et al (2012) Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 84:1078–1085PubMedCentralPubMedCrossRef
[34]
Zurück zum Zitat Yu WW, Zhu ZF, Fu XL et al (2014) Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study. Strahlenther Onkol (epub ahead of print) Yu WW, Zhu ZF, Fu XL et al (2014) Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study. Strahlenther Onkol (epub ahead of print)
[35]
Zurück zum Zitat Lettmaier S, Strnad V (2014) Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique. J Contemp Brachytherapy 6:236–241PubMedCentralPubMedCrossRef Lettmaier S, Strnad V (2014) Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique. J Contemp Brachytherapy 6:236–241PubMedCentralPubMedCrossRef
[36]
Zurück zum Zitat Lordick F, Hölscher AH, Haustermans K, Wittekind C (2013) Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 398:177–187PubMedCrossRef Lordick F, Hölscher AH, Haustermans K, Wittekind C (2013) Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 398:177–187PubMedCrossRef
[37]
Zurück zum Zitat Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317PubMedCrossRef Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317PubMedCrossRef
[38]
Zurück zum Zitat Bedenne L, Michel P, Bouché O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160–1168PubMedCrossRef Bedenne L, Michel P, Bouché O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160–1168PubMedCrossRef
[39]
Zurück zum Zitat Lordick F, Ott K, Krause BJ et al (2007) Use of PET to assess early metabolic response and guide treatment of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: a feasibility study. Lancet Oncol 8:797–805PubMedCrossRef Lordick F, Ott K, Krause BJ et al (2007) Use of PET to assess early metabolic response and guide treatment of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: a feasibility study. Lancet Oncol 8:797–805PubMedCrossRef
[40]
Zurück zum Zitat Lordick F (2012) Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. Recent Results Cancer Res 196:201–211PubMedCrossRef Lordick F (2012) Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. Recent Results Cancer Res 196:201–211PubMedCrossRef
[41]
Zurück zum Zitat Bradley J, Bae K, Choi N et al (2012) A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys 82:435–441PubMedCentralPubMedCrossRef Bradley J, Bae K, Choi N et al (2012) A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys 82:435–441PubMedCentralPubMedCrossRef
[42]
Zurück zum Zitat Lazarescu I, Thureau S, Nkhali L et al (2013) Clinical target volume delineation for radiotherapy of the esophagus. Cancer Radiother 17:453–460PubMedCrossRef Lazarescu I, Thureau S, Nkhali L et al (2013) Clinical target volume delineation for radiotherapy of the esophagus. Cancer Radiother 17:453–460PubMedCrossRef
Metadaten
Titel
Interdisziplinäre Therapie des Ösophaguskarzinoms
verfasst von
Prof. Dr. F. Lordick
I. Gockel
J. Mössner
T. Kuhnt
C. Wittekind
Publikationsdatum
02.12.2014
Verlag
Springer-Verlag
Erschienen in
best practice onkologie / Ausgabe 6/2014
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI
https://doi.org/10.1007/s11654-014-0515-0

Weitere Artikel der Ausgabe 6/2014

best practice onkologie 6/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.